The Josep Carreras Leukaemia Research Institute (IJC) is a comprehensive cancer research center dedicated to conduct research and drive innovation in the epidemiological, preventive, clinical, translational, and basic aspects of leukaemia and other hematologic malignancies, with the final aim of finding a cure for these diseases. It was created in 2010, and since then has experienced an exponential growth.

The IJC is also part of the network of Excellence Research Centers of Catalonia (CERCA) and was accredited as a Severo Ochoa Center of Excellence by the Ministry of Science, Innovation, and Universities in 2024. Since 2018, the Institute has also been accredited by the Scientific Foundation of the Spanish Association Against Cancer (FCAECC) Additionally, IJC is one of the centers integrated into the Institut de Recerca Germans Trias i Pujol (IGTP) accreditation as Accredited Health Research Institute (IIS) by the Carlos III Health Institute (ISCIII).

The IJC's main headquarters is located within the Can Ruti Biomedical Campus, alongside other leading biomedical institutions, providing direct access to cutting-edge scientific and technological facilities, as well as complementary community services. The IJC has six locations integrated into reference hospitals: Hospital Germans Trias i Pujol, Hospital Clínic, Hospital Sant Pau, Hospital Josep Trueta, Hospital del Mar and Hospital San Joan de Déu. This facilitates close collaboration between basic and clinical researchers, fostering translational research that integrates basic science with clinical practice in clinical settings.

We are looking for postdoctoral researchers in the field of biomedicine to join the Immunological Neoplasms and Precision Immunotherapy Group, led by Dr. Ari Melnick.

RESEARCH DESCRIPTION

Our lab integrates advanced animal models, spatial genomics, epigenetics, and sophisticated microscopy to dissect the biology of immune malignancies, particularly lymphomas. We emphasize translational research, bridging fundamental discoveries to clinical applications, with a goal to develop novel, targeted immunotherapies that improve patient outcomes.

Advance your career by joining a pioneering lab dedicated to unraveling immune tumor biology and translating discoveries into precision immunotherapies that can transform cancer treatment. We invite motivated and talented postdoctoral scientists to join our cutting-edge research program focused on understanding how the immune system becomes malignant, the molecular mechanisms controlling immune cancer niches, mechanisms of immune evasion, and innovative strategies to defeat these tumors using precision immunotherapies.

This position is partially supported by funding from The Leukemia & Lymphoma Society (LLS) and the Institute for Follicular Lymphoma Innovation (IFLI) through the Research Accelerator for Follicular Lymphoma (RAFL) Synergistic Team Award (SAT), under the ERADICATE Follicular Lymphoma Consortium grant."

WHAT WE NEED

• A Ph.D. or M.D./Ph.D. in immunology, cancer biology, molecular biology, or related fields.
• Experience with animal models, immunology, genomics, epigenetics, or advanced imaging techniques preferred.
• A passion for science and commitment to scientific rigor
• Interest in translational research and collaborative team science
• Excellent communication skills and motivation to contribute to highimpact research
• Good communication skills in English.
• Ability to work independently and efficiently.
• Motivation to achieve a high quality work.

WHAT WE OFFER

• Postdoctoral contract (5 years) that can be renewed
• Incorporation in a multinational and highly collaborative team.
• An innovative and interdisciplinary research project.
• Mixed basic and clinical research environment of the Josep Carreras Leukaemia Research Institute.
• The stimulating environment of the Barcelona metropolitan area.

DEADLINE

Please submit your application by 18^th June 2025.

WHO WE ARE?

What makes us different?

The mission of the Josep Carreras Institute is to conduct research and drive innovation in the epidemiological, preventive, clinical, translational, and basic aspects of leukaemia and other hematologic malignancies, with the final aim of finding a cure for these diseases.
The IJC’s vision is to be a world-class reference and excellent research multicampus that contributes to the improvement of results, and the cure of patients affected by leukemia and other malignant hemopathies, through innovation, sustainability, social responsibility, talent, and professional experience.

HR Excellence

In 2019, IJC was honored with the “Human Resources Excellence in Research Award” by the European Commission, recognizing the alignment of our human resources policies with the European Charter for Researchers and Code of Conduct for the Recruitment of Researchers. The Human Resources Strategy for Researchers (HRS4R) guides research centers of excellence in implementing and upholding these standards within their policies, emphasizing training, professional development, and mobility opportunities.
The IJC’s commitment to these values and principles strengthens our internal policies and ensures that our members have the optimal conditions and environment for their professional development.
The Board of Trustees is composed of representatives of the Generalitat de Catalunya (regional government), University of Barcelona, Autonomous University of Barcelona, the City of Badalona and the Jose Carreras International Leukaemia Foundation
The Catalan government provides hard money on an annual basis. The Jose Carreras International Leukaemia Foundation provides start-up funds, project funds as well as financial support for investments.
The JCI has an international scientific advisory board served by prominent researchers from US and Europe.
The IJC has been awarded ERC and other EU grants.

The IJC is an equal-opportunity employer. We evaluate qualified applicants without regard to race, color, religion, sex, national origin, disability, or other legally protected characteristics.